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Abstract
Type 1 diabetes mellitus (T1DM) is a multifactorial autoimmune disease in which the insulin producing β cell 
population is destroyed by the infiltrated T lymphocytes. Even though the exact cause of T1DM is yet to be ascertained, 
varying degree of genetic susceptibility and environmental factors have been linked to the disease progress and 
outcome. Mycobacterium avium subsp. paratuberculosis (MAP) is an obligate zoonotic pathogen that causes chronic 
infection of intestines in ruminants, the Johne's disease. MAP that can even survive pasteurization and chlorination has 
also been implicated to cause similar type of enteritis in humans called Crohn's disease. With the increasing 
recognition of the link between MAP and Crohn's disease, it has been postulated that MAP is an occult antigen which 
besides Crohn's could as well be thought to trigger T1DM. Epitope homologies between mycobacterial proteins (Hsp 
65) and pancreatic glutamic acid decarboxylase (GAD 65) and infant nutrition studies implicate MAP as one of the 
triggers for T1DM. PCR and ELISA analyses in diabetic patients from Sardinia suggest that MAP acts as a possible trigger 
for T1DM. Systematic mechanistic insights are needed to prove this link. Unfortunately, no easy animal model(s) or in-
vitro systems are available to decipher the complex immunological network that is triggered in MAP infection leading 
to T1DM.
Type 1 diabetes and MAP
Type 1 diabetes accounting for about 5-10% of all diabet-
ics is an end stage insulitis characterized by the presence
of only 10-20% of insulin producing β-cells [1,2]. Also,
T1DM is the second most common chronic disease dur-
ing childhood and the most common form of diabetes
affecting around 1.7 of every 1000 children [reviewed
elsewhere, [3]]. Its worldwide prevalence is predicted to
increase from 4.4 millions in 2000 to approximately 5.4
millions in 2010. The incidence of the disease is consis-
tently increasing in many countries, the highest being in
European countries, particularly in Finland, Sardinia and
Sweden [4]. In a southern Indian urban population, the
occurrence of T1DM in children less than 15 years of age
was found to be 26 per 10000 [5]. Susceptibility to T1DM
is inherited, but the mode of inheritance is not clearly
known [6-8]. Genetic predisposition alone cannot explain
the acquisition of T1DM. Several factors such as
microbes, dietary factors and environmental toxins have
also been implicated in the development of the disease.
The American Diabetes Association (1997) classified
T1DM into two forms: (a) type 1A (auto immune diabe-
tes) which is characterized by the presence of auto reac-
tive antibodies in the serum of the affected individuals.
These antibodies are directed against Hsp60, insulin
(IAA), insulinoma-associated protein-2 (IA-2) and glu-
tamic acid decarboxylase (GAD65), an enzyme present in
pancreatic β-cells. In patients with recent onset of T1DM
a u t o  r e a c t i v e  T -  c e l l s  h a v e  a l s o  b e e n  d e t e c t e d .  T h e s e
auto-reactive T cells have been considered to be involved
in β-cell destruction. [5,9-11]. (b) The other form, diabe-
tes type 1B (diabetes with idiopathic loss of β-cell func-
tion) [9,10] is comparatively less common, lacks the
autoimmunity connection and might need insulin
replacement therapy in affected patients. In summary, the
development of T1DM is mechanistically very compli-
cated and several different factors have been proposed to
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influence the clinical outcome of the disease (Fig. 1).
Lately, however, the role of microorganisms and patho-
gens is becoming evident in T1DM, although, without
much (proof of principle) evidence; nevertheless, clinical
level, supportive association studies based on diagnostics
that specifically target MAP DNA and serum antibodies
in the T1DM patients have been highly suggestive of a
pathogen trigger (Fig. 2).
Is MAP the trigger? - the Sardinian model
MAP, an obligate zoonotic pathogen is the causative
agent of a chronic, inflammatory bowel disease referred
to as Johne's disease of ruminants. The ability of MAP to
exist in spheroplast form in addition to the bacillary
forms adds to its survival potential [12]. The primary
route of MAP infection is fecal- oral and once ingested,
the bacterium lodges in to the mucosa associated lym-
phoid tissue (MALT) of the small intestine. It is then
endocytosed by the M cells of Peyer's patches, which are
further phagocytosed by intra epithelial macrophages.
Activation of the macrophages causes an inflammatory
immune response leading to clinical signs of Johne's dis-
ease. Inspite of its broad pathogenicity, MAP can live in
animals for years without causing any clinical disease
[13,14]. Wildlife reservoirs contribute to the cycle of re-
infection [15]. Infected animals shed MAP bacilli in their
milk and feces. MAP is found to be present in untreated
water such as well water and in water bodies contami-
nated by agricultural runoff. The treatment of water to
make it potable by the processes of sedimentation, filtra-
tion and chlorination has little or no effect on MAP [16].
Our group has shown in the past that MAP significantly
associates with T1DM in Sardinian patients [17]. In the
back-drop of sheep husbandry and high incidence of
autoimmune diseases in Sardinia, it makes a lot of sense
to brand MAP as a putative environmental trigger . It is
however, not clear whether MAP also associates with
T1DM (or other autoimmune diseases that occur) in
other geographical regions. Nevertheless, the Sardinian
model greatly helps us understand the inner side of socio-
economic and lifestyle factors in shaping a vulnerable,
susceptible population despite the fact that sheep hus-
bandry brought prosperity in terms of livelihood in this
Mediterranean island. Modern animal breeding and
expansion of dairy industries in the developed countries
have led to increased exposure of the individuals to some
of the animal pathogens. This is more prominently
observed in Sardinia where sheep farming is intensively
practiced and the sheep measure about 4-fold of the
human population [17]. Further, studies have shown that
Sardinia is highly endemic for the presence of MAP infec-
tion in sheep. MAP shedded in the milk of infected cows/
sheep has been found to survive pasteurization [18].
There are several evidences indicating an association
between early exposure to cow's milk and increased risk
of T1DM [2,19,20]. Interestingly, it has also been
observed that children at risk for T1DM who were breast
fed exclusively for more than six months were less likely
to have T1DM later in life than children at similar risk
who were weaned on to cow's milk [21]. Such observa-
tions led to the foundation of the TRIGR study: Trial to
Reduce Insulin Dependent Diabetes Mellitus in the
Genetically at Risk. It is an ongoing study in 17 countries
encompassing 6,200 infants who are genetically at risk to
develop T1DM [22,23].
MAP, which causes Johne's disease in ruminants, is also
implicated to cause a similar type of enteritis in humans
called Crohn's disease [24,25]. Association of MAP with
Crohn's disease indicates that there may be a putative link
between MAP and T1DM [26]. As this hypothesis is get-
ting ground, rapid and sensitive detection of active MAP
infection in T1DM patients has become a challenge. Sar-
dinia, a genetic isolate with alleles and haplotypes that are
rare or absent elsewhere poses as a high endemic zone of
autoimmune disorders such as T1DM, lupus erythemato-
sus and multiple sclerosis. An interplay of genetic and
environmental factors in Sardinia possibly could make it
Figure 1 Putative factors facilitating development and progres-
sion of T1DM. Susceptibility factors such as altered intestinal immune 
responses with enhanced expression of antigen presenting HLA class 
II molecules and intracellular adhesion molecule (ICAM)-1 on the intes-
tinal epithelium, leaky intestinal mucosal barrier with low levels of clau-
din and a background of environmental factors such as aberrant 
intestinal microbiota and lack of exposure to symbiotic organisms are 
hypothesized to be involved in the development of T-regulatory re-
sponses. And, absence of such response is implicated in the manifes-
tation of autoimmune diseases. A complex interplay between these 
factors along with socio-economic factors (Sardinia) such as infant nu-
trition, milk infected with MAP- a putative trigger in genetically suscep-
tible individuals, leads to the manifestation of clinical T1DM over a 
period of time with destruction of β cells of pancreas and decreased 
production of insulin. MAP has emerged central to this scenario lately 
due to the supporting studies from Sardinia that associates MAP with 
T1DM [17,28] but not with Type 2 diabetes (T2DM) [53].Rani et al. Gut Pathogens 2010, 2:1
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a hotspot to study autoimmune disorders. Sechi et al.,
(2008) have successfully demonstrated PCR based detec-
tion of IS 900, a specific signature locus of MAP in T1DM
cases in Sardinia [27]. After identification of MAP in the
blood of T1DM it was quite necessary to understand the
host immune responses to MAP. This led them further to
design immunoassays for the detection of anti-MAP anti-
bodies in diabetic patients by ELISA, employing sensitive
antigenic targets such as HbHa (heparin binding hemag-
glutinin) and Gsd (glycosyl transferase) proteins [17].
However, anti-MAP humoral responses corresponding to
HbHa and Gsd could not be indicative of an active infec-
tion and also since these proteins are encoded by wider
range of mycobacteria, this raised an issue of cross-reac-
tivity with tubercle bacilli which could be an issue to deal
with the BCG vaccinated individuals. This group later
improvised the immunoassays by including a MAP spe-
cific protein, MptD into their battery of antigens. Apart
from purified antigens, specific phages corresponding to
MptD (fMptD) were also used in a sandwich ELISA
scheme [28]. The improvised ELISA assays that use mul-
tiple target proteins and phages for the detection of anti-
MAP antibodies revealed extremely significant humoral
immune responses in T1DM patients when compared to
T2DM and healthy controls [28] (Fig. 2). A final evidence
was presented in terms of culture of MAP bacilli from the
blood of two of the T1DM patients from Sardinia [28].
Genetic susceptibility and microbial mechanisms of 
T1DM
The recent development of high throughput genotyping
technologies and the availability of large sample sizes
Figure 2 Summary of the analyses by Sechi and colleagues involving Sardinian diabetic populations and healthy volunteers [17,28,53]. Pan-
els A and B: The data clearly revealed that T1DM patients show significant humoral immune responses to MAP (recombinant) proteins such as HbHa, 
Gsd & MptD; MAP lysate preparation; and specific phages corresponding to MAP specific protein MptD (mentioned as M13 MptD or fMptD) when 
compared to healthy controls and T2DM patients. Panel C: Multiplex ELISA analysis involving MptD specific phage (M13MptD), MAP lysate, Gsd and 
HbHa used against T1DM patients sera. Values on the Y- axis denote optical density values corresponding to anti-MAP serum immunoglobulin status. 
The dark, solid, horizontal lines represent median OD values for each group. Details of ELISA methods and choice of MAP antigens etc. have already 
been dealt with previously [17,28,53].Rani et al. Gut Pathogens 2010, 2:1
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have become a favorable tool for association studies of
human genes controlling complex traits [29]. Susceptibil-
ity genes for insulin dependent diabetes have been
mapped to the chromosomal regions: HLA DRQ, INS
VNTR and CTLA-4 (cytotoxic lymphocyte antigen-4)
[30,31]. Additionally, SLC11A1 (NRAMP) and VDR (vita-
min D receptor) genes have also been implicated to be
involved in T1DM [32,33]. In humans, SLC11A1 - solute
carrier 11A1gene (previously known as NRAMP1) is
mapped on 2q35, is composed of 15 exons and it spans at
least 16 kb of the DNA. It encodes an integral membrane
protein of 550 amino acids that is expressed exclusively in
the lysosomal compartment of monocytes and mac-
rophages. This membrane protein functions as a cation
transporter that regulates iron homeostasis [34,35]. In
response to intracellular pathogens, SLC11A1 exhibits
multiple pleiotropic effects such as gamma interferon
induced class II expression and acidification of phago-
somes [35,36]. Mutations of SLC11A1 impair phagosome
acidification, creating thereby a suitable environment for
the persistence of intracellular bacteria [37]. Sechi and
colleagues have also proposed that SLC11A1 gene poly-
morphism is associa t ed wit h MAP DNA presence and
T1DM in Sardinia [38].
Infectious agents such as MAP by virtue of their anti-
gens have been implicated to play an important role in
the development of autoimmune diseases such as Crohn's
disease and T1DM. Sequence similarity among the infec-
tious agents and self proteins (molecular mimicry) has
been proposed to be one of the central mechanisms
underlying development of autoimmunity [39]. T1DM is
characterized by elevated levels of immune responses tar-
geted against several auto antigens including Hsp 60,
insulin, insulinoma - associated protein-2 (IA-2) and glu-
tamic acid decarboxylase (GAD) [5,17,40]. GAD exists in
two forms, GAD65 (65 KDa; 585 amino acids) and
GAD67 (67 KDa; 593 amino acids). Only GAD 65 is
expressed in the β-cells of human islets. GAD is a rate-
limiting enzyme that catalyzes the conversion of glutamic
acid to γ-amino butyric acid (GABA) [41]. Hsp 65 is a
heat shock protein that is unique to mycobacteria [42]. It
has been found that GAD65 and Hsp 65 have similar
amino acid sequences [43]. In a study, it was found that
up to 70 percent of T1DM patients have antibodies to
GAD 65, compared to 4 percent of healthy individuals,
thereby suggesting a cross reactive immune response tar-
geted against GAD 65 [5]. This cross reactivity might
pave the way for the destruction of the islet cells in genet-
ically susceptible individuals [17]. More recent studies
also support this hypothesis by proving that DNA vac-
cines involving mycobacterial HSP 65 protected NOD
mice against diabetes [44]. Apart from this, a cause and
effect experiment to serve as 'proof of principle' has never
been reported to unequivocally support or rule out
molecular mimicry as a cardinal process behind T1DM.
The main reason for this could be non-availability of any
practical and convenient model for in vitro or  in vivo
studies involving molecular mimicry.
It is not clear if molecular mimicry occurs also in cases
of other chronic infections; individuals with T1DM are
often susceptible to infection with chronic pathogens
[45]. It has been shown that Helicobacter pylori (H.
pylori), which causes gastritis, peptic ulcer and gastric
cancer, is common in T1DM [46]. Certain studies found a
higher prevalence of H. pylori infection in diabetic
patients with a reduced glycemic control, while others did
not support any correlation between metabolic control
and  H. pylori infection [47]. Interestingly it has been
observed that the possibility of induction of Crohn's dis-
ease has also been reported after eradication of H. pylori
[48,49].
Prospective
Though MAP is identified as a trigger for T1DM, the
underlying mechanism of MAP induced β-cell destruc-
tion is still an unsolved puzzle. As no easy animal model
is available, development of an in vitro or an in vivo sys-
tem will be of importance for deciphering the immuno-
logical network that is triggered in MAP pathogenesis,
and that can be exploited for developing the functional
evidence to link MAP to T1DM. I t is also essential to
understand the mechanisms by which mycobacteria such
as MAP are acting as triggers in different autoimmune
diseases and T1DM in particular. There is an urgent need
to test a large number of geographically distinct patient
populations with clinical T1DM in the same way as Sar-
dinian patients have been tested for MAP. Also, it will be
essential to develop high throughput genetic screens to
identify single nucleotide polymorphisms that are associ-
ated with autoimmune diseases and those related to per-
sistence of intracellular pathogens and a compensatory
upregulation of proinflammatory cytokines. While it is
important to identify other mycobacterial antigens that
trigger host cell signaling cascades, it is certainly possible
to scale up diagnostic screening tests based on existing
antigens so that population level testing becomes practi-
cable.
For decades, the population of Sardinia has been the
subject of several human genetic analysis experiments.
Population geneticists have revealed highly complex
genetic relationships among Sardinians and other Euro-
pean populations. Peculiar gene pool characteristics of
the Sardinians might have evolved over time as a function
of strict isolation and consequent endogamy, consanguin-
ity and the burden of historical scourges such as Malaria.
High resolution, population based analyses are required
to ascertain or negate any role of the unique SardinianRani et al. Gut Pathogens 2010, 2:1
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haplotypes and the high incidence of the autoimmune
diseases.
Non-specific immune regulators such as Mycobacte-
rium indicus pranii (MIP) [50] have been shown to play
significant roles as immuno-therapeutic/prophylactic for
leprosy, tuberculosis, leishmaniasis, psoriasis, bladder
cancer and ano-genital warts [reviewed elsewhere -
[51,52]]. It appears that non-specific immune stimulation
could be the basic mechanism underlying the clearance of
the lesions in all the above diseases when MIP was used.
By analogy, MIP could also be used as a potential thera-
peutic/prophylactic agent for the autoimmune diseases
rampant in Sardinia and beyond. It is essential therefore
to test this organism in a setting such as Sardinia [53] as it
has already worked wonderfully in a high burden country
such as India which is crippled with tuberculosis, HIV,
and diabetes. Given this, it will be tempting to propose
experimental administration of MIP to susceptible popu-
lations and evaluate if it retards early onset of T1DM.
Finally, the roles of intestinal microbiota and probiotic
organisms should be explored at the interface of gut per-
meability and mucosal immunity [54] and the regulations
thereof. Advancements in metagenomics of the gut
microbiota and the consequent metabolomics and sys-
tems biology projects would be able to unravel the com-
plex interactions underlying the alternative microbial
mechanisms of T1DM apart from chronic MAP infec-
tion.
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